BSFA Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Sustained Revenue Growth & Rare Disease FocusANI's scale-up is rooted in accelerating product adoption and a durable Rare Disease mix: management expects Rare Disease to be ~60% of 2026 revenue and raised full-year guidance. Persistent tailwinds for Cortrophin and specialty commercial investments support multi‑period revenue visibility and addressable market capture.
Robust Cash Generation And Free Cash FlowConsistent, sizable operating and free cash flow enhances strategic optionality: funds organic commercial expansion, deleveraging, buybacks and BD. Strong FCF supports capital allocation choices over several years, reducing reliance on external financing during growth or integration periods.
Integrated Manufacturing & Repeat Launch CadenceIn-house manufacturing plus a steady generics launch cadence drive durable revenue diversification and higher margin capture on owned products. Vertical capabilities and consistent approvals (#2 in CGT approvals) lower dependency on single products and sustain long-term commercial momentum and gross margin potential.
Bears Say
Gross-Margin Compression And Mix RiskShift toward royalty-bearing partnered products and certain partnered launches has compressed gross margins versus prior peaks. A structurally different product mix can cap operating leverage, reduce long-term margin sustainability, and make profits more sensitive to contract terms and royalty rates.
Balance-Sheet Volatility And Historical Leverage SpikeAlthough leverage has meaningfully improved, the prior sharp spike shows the capital structure is cyclical and sensitive to operating performance. Such volatility reduces financial flexibility in downturns and raises refinancing or covenant risk if revenue or cash flow miss expectations.
Access Headwinds & Reliance On One-Time PaymentsPersistent Medicare access issues for ILUVIEN and dependence on upfront or milestone payments create structural revenue predictability risks. Reimbursement barriers slow patient uptake, while timing of nonrecurring payments increases earnings volatility and complicates multi‑period forecasting.
ANI Pharmaceuticals News
BSFA FAQ
What was Ani Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Ani Pharmaceuticals’s market cap?
Ani Pharmaceuticals’s market cap is CHF1.44B.
When is Ani Pharmaceuticals’s upcoming earnings report date?
Ani Pharmaceuticals’s upcoming earnings report date is Aug 07, 2026 which is in 11 days.
How were Ani Pharmaceuticals’s earnings last quarter?
Ani Pharmaceuticals released its earnings results on May 08, 2026. The company reported $1.669 earnings per share for the quarter, beating the consensus estimate of $1.058 by $0.612.
Is Ani Pharmaceuticals overvalued?
According to Wall Street analysts Ani Pharmaceuticals’s price is currently Undervalued.
Does Ani Pharmaceuticals pay dividends?
Ani Pharmaceuticals does not currently pay dividends.
What is Ani Pharmaceuticals’s EPS estimate?
Ani Pharmaceuticals’s EPS estimate is 1.66.
How many shares outstanding does Ani Pharmaceuticals have?
Currently, no data Available
What happened to Ani Pharmaceuticals’s price movement after its last earnings report?
Ani Pharmaceuticals reported an EPS of $1.669 in its last earnings report, beating expectations of $1.058. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Ani Pharmaceuticals?
Currently, no hedge funds are holding shares in CH:BSFA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ANI Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF89.01 (― Downside)
CHF89.01 (― Downside)
Insider Transactions
Sold Shares
Worth CHF4.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.02%
Trailing 12-Months
Company Description
Ani Pharmaceuticals
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
BSFA Company Deck
BSFA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum and material financial progress: consolidated Q1 revenue growth (20% YoY), Cortrophin Gel growth (42% YoY), adjusted EBITDA and EPS expansion, raised 2026 guidance, near-term cash from an IP out-license, an active product launch cadence in Generics, and a sizeable commercial expansion into acute gouty arthritis flares. Offsetting items include margin pressure from a higher mix of royalty-bearing products and new launches, temporary insurance reverification and access headwinds that impacted Q1 timing, increased SG&A from sales expansion, and some reliance on timing of upfront/milestone payments. Overall, positives (revenue/EBITDA growth, guidance raise, strategic investments and M&A optionality, cash position, repurchase program) materially outweigh the lowlights (margin compression, access and timing issues), supporting a constructive outlook for 2026 and into 2027.View all CH:BSFA earnings summariesBSFA Stock 12 Month Forecast
Average Price Target
$89.01
―
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Harrow Health
―